Niemann-Pick Disease Type C Treatment Market Report 2026

Niemann-Pick Disease Type C Treatment Market Overview

• Niemann-Pick Disease Type C Treatment market size has reached to $2.92 billion in 2025 • Expected to grow to $4.46 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Prevalence Of Alzheimer’s Disease Fueling The Growth Of The Market Due To Shared Neurodegenerative Research • Market Trend: Advancements In Neuroprotective Therapies Driving Treatment Innovations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Niemann-Pick Disease Type C Treatment Market?

Niemann-Pick disease type C (NPC) treatment refers to the medical approaches used to manage and slow the progression of Niemann-Pick disease type C, a rare, inherited neurodegenerative disorder that affects the body's ability to metabolize cholesterol and other lipids within cells. It involves pharmacological and supportive therapies to reduce neurological symptoms, stabilize the disease, and improve quality of life. The main disease types in niemann-Pick disease type C treatment are niemann-Pick disease type C1 and niemann-Pick disease type C2. niemann-Pick disease type C1 (NPC1) is a rare, progressive, and fatal lysosomal storage disorder caused by mutations in the NPC1 gene, leading to impaired intracellular cholesterol trafficking, the accumulation of lipids in lysosomes, and severe neurological deterioration, including cognitive decline, motor dysfunction, and organ damage. This includes various age groups, including infantile, juvenile, and adult, having end users such as hospitals, specialty clinics, and research and academic institutes.

What Is The Niemann-Pick Disease Type C Treatment Market Growth Forecast?

The niemann-pick disease type c treatment market size is expected to see strong growth in the next few years. It will grow to $4.46 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in gene therapy research, increasing investments in rare disease R&D, improved diagnostic technologies, expanding newborn screening programs, supportive regulatory frameworks for novel therapies. Major trends in the forecast period include increased adoption of orphan drug development, rising focus on early diagnosis and screening, expansion of supportive and symptom management therapies, growing clinical trial activity for rare diseases, improved patient access programs and reimbursement support.

Global Niemann-Pick Disease Type C Treatment Market Segmentation

1) By Disease Type: Niemann-Pick Diseases Type C1, Niemann-Pick Diseases Type C2 2) By Age Group: Infantile, Juvenile, Adult 3) By End-User: Hospitals, Specialty Clinics, Research And Academic Institutes Subsegments: 1) By Niemann-Pick Disease Type C1: Pharmacological Treatment, Gene Therapy, Substrate Reduction Therapy, Supportive Care 2) By Niemann-Pick Disease Type C2: Enzyme Replacement Therapy, Pharmacological Treatment, Gene Therapy, Supportive Care

What Is The Driver Of The Niemann-Pick Disease Type C Treatment Market?

The increasing prevalence of Alzheimer's disease is expected to drive the growth of the Niemann-Pick disease type C treatments market going forward. Alzheimer's disease is a progressive neurodegenerative disorder characterized by the accumulation of beta-amyloid plaques and tau protein tangles in the brain, leading to cognitive decline, memory loss, and impairment in daily functioning, ultimately resulting in severe dementia and neurodegeneration. The increasing prevalence of Alzheimer's disease is due to the aging global population. As people live longer, especially in developed countries, the risk of age-related diseases like Alzheimer's rises significantly since advancing age is the strongest known risk factor for the condition. Niemann-pick disease type C (NPC) treatment supports Alzheimer's Disease research by providing insights into lysosomal storage disorders and lipid metabolism dysfunction. For instance, in May 2024, according to the Alzheimer's Society, a UK-based voluntary health organization, an estimated 982,000 people in the UK are living with dementia in 2024, though more than a third remain undiagnosed, with the total number expected to reach 1.4 million by 2040. Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the Niemann-Pick disease type C treatments industry.

Key Players In The Global Niemann-Pick Disease Type C Treatment Market

Major companies operating in the niemann-pick disease type c treatment market are Mayo Clinic, Boston Children’s Hospital, Cincinnati Children’s Hospital Medical Center, Mallinckrodt Pharmaceuticals, Rainbow Children’s Hospital, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders NORD, National Niemann‑Pick Disease Foundation NNPDF, Bloomsbury Genetic Therapies Ltd., Vtesse Inc., Cyclo Therapeutics Inc., Orphazyme A S, Intrabio Inc., Sarepta Therapeutics Inc., StrideBio, Azafaros B V, ViroMed, NeuroSense Therapeutics, ArmaGen, Synlogic, Editas Medicine, Passage Bio, Chameleon Bio, Aro Bio, Glycomine, Scenic Biotech, Actio Biosciences, AIRNA Therapeutics

Global Niemann-Pick Disease Type C Treatment Market Trends and Insights

Major companies in the Niemann-pick disease type C (NPC) treatment market are focusing on developing innovative therapies, such as neuroprotective therapies, to slow disease progression and improve patient outcomes. Neuroprotective therapies are treatments designed to protect the brain and nervous system from damage or degeneration, often aimed at preserving neurological function in conditions such as neurodegenerative diseases. For instance, in September 2024, IntraBio Inc., a US-based biopharmaceutical company, announced the approval from the United States Food and Drug Administration (FDA), a US-based regulatory agency, for AQNEURSA (levacetylleucine), making it the first stand-alone therapy for Niemann-Pick Disease Type C (NPC). This approval follows positive Phase III trial results, showing significant neurological improvements in NPC patients within 12 weeks. AQNEURSA provides a long-awaited treatment option for individuals affected by this rare lysosomal storage disorder, which impacts movement, cognition, and daily function. IntraBio also plans to explore AQNEURSA's potential for treating other neurodegenerative and neurodevelopmental disorders.

What Are Latest Mergers And Acquisitions In The Niemann-Pick Disease Type C Treatment Market?

In December 2023, Cyclo Therapeutics, Inc., a US-based biotechnology company, merged with Applied Molecular Transport Inc. for $10.2 million. This merger aims to strengthen Cyclo Therapeutics’ financial and strategic position by leveraging additional resources, extending its cash runway, and advancing the clinical development and regulatory approval process of Trappsol Cyclo, a potential treatment for Niemann-Pick Disease Type C1 (NPC1), through the pivotal Phase 3 global study (TransportNPC). Applied Molecular Transport Inc. is a US-based clinical-stage biopharmaceutical company.

Regional Outlook

North America was the largest region in the niemann-pick disease type C treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Niemann-Pick Disease Type C Treatment Market?

The niemann-Pick disease type C treatment market includes revenues earned by entities through medication management, symptom management, neurological care, liver care, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Niemann-Pick Disease Type C Treatment Market Report 2026?

The niemann-pick disease type c treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the niemann-pick disease type c treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.